[26-0900] Poster Discussion | The 29th Annual Meeting of the Japanese Society for Vaccinology/The 66th Annual Meeting of the Japanese Society of Clinical Virology

The 29th Annual Meeting of the Japanese Society for Vaccinology/The 66th Annual Meeting of the Japanese Society of Clinical Virology

Session Details

Poster Discussion

Sun. Sep 28, 2025 9:00 AM - 3:00 PM JST
Sun. Sep 28, 2025 12:00 AM - 6:00 AM UTC

Poster Exhibition(1F Main Hall 1/2B)

[P-01]先天性単純ヘルペスウイルス2型感染症の1例における長期経過

*Tsunehisa Nagamori¹, Jyunki Tsuda¹, Masayuki Sato¹, Emi Ishibazawa¹, Satoru Takahashi¹ (1. Department of Pediatrics, Asahikawa Medical University)

[P-02]循環器内科外来における帯状疱疹と併存疾患、ワクチン接種の状況

*Takenori Okada¹ (1. Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital)

[P-03]Interpreting the presence of EBV DNA in CSF samples

*Julian Wei-Tze Tang^1,2, Joshua Nazareth^1,2, Wael Goravey¹, Paul W Bird^1,2, Umeyma Musse³, Dan Pan^1,2 (1. Clinical Microbiology, University Hospitals of Leicester NHS Trust, Leicester, UK, 2. Respiratory Sciences, University of Leicester, Leicester, UK, 3. Infectious Diseases Unit, University Hospitals of Leicester NHS Trust, Leicester, UK)

[P-04]髄液からHHV-6が検出されたが中枢神経系感染症を否定した新生児2例

*Akinori Matsukawa¹, Michio Suzuki¹, Yuu Fukami¹, Wakako Furukawa¹, Toshiki Takeo¹, Tatsuya Fukasawa¹, Shotarou Ando², Takako Suzuki³, Yuka Torii³, Junichi Kawata⁴, Tetsuo Kubota¹ (1. Department of Pediatrics, Anjo Kosei Hospital, 2. Department of Pediatrics, Okazaki City Hospital, 3. Department of Pediatrics, Nagoya University Graduate School of Medicine, 4. Department of Pediatrics, Fujita Health University School of Medicine)

[P-05]Impact of parvovirus B19 infections in pregnant women during 2024, Leicester, UK

*Julian Wei-Tze Tang^1,2, Manjiri Khare³, Suzanna Dunkerton³, Farah Siddiqui³, Eamonn Breslin³, Ian Scudamore³, Dipak Patel⁴, Joshua Nazareth¹, Wael Goravey¹, Hatem A Mousa³, Oliver TR Toovey¹ (1. Clinical Microbiology, University Hospitals of Leicester NHS Trust, Leicester, UK, 2. Respiratory Sciences, University of Leicester, Leicester, UK, 3. Fetal Medicine Unit, University Hospitals of Leicester NHS Trust, Leicester, UK, 4. Pathology Data and Informatics, University Hospitals of Leicester NHS Trust, Leicester, UK)

[P-06]The rise and rise of adenoviruses

*Julian Wei-Tze Tang^1,2, Eldilla Rizal³, Julia Vujcikova³, Ian DeSilva⁴, Tahir Islam⁴, Matthew Charlton⁵, Susan Dashey⁵, Paul Player⁶, Sarah Wharin⁶, Wael Goravey², Paul W Bird^1,2, Oliver TR Toovey² (1. Respiratory Sciences, University of Leicester, Leicester, UK, 2. Clinical Microbiology, University Hospitals of Leicester NHS Trust, Leicester, UK, 3. Paediatric Intensive Care, University Hospitals of Leicester NHS Trust, Leicester, UK, 4. Eye Casualty and Ophthalmology, University Hospitals of Leicester NHS Trust, Leicester, UK, 5. Adult Intensive Care and ECMO Unit, University Hospitals of Leicester NHS Trust, Leicester, UK, 6. Adult Haematology, University Hospitals of Leicester NHS Trust, Leicester, UK)

[P-07]E199K変異を有しバロキサビル感受性が低下したインフルエンザウイルスAH1pdm09の検出例

*Wakako Furukawa¹, Michio Suzuki¹, Yoshihiro Yasui², Emi Takashita³, Akinori Matsukawa¹, Toshiki Takeo¹, Tatsuya Fukasawa¹, Tetsuo Kubota¹ (1. Department of Pediatrics, Anjo Kosei Hospital, 2. Aichi Prefectural Institute of Public Health, 3. Japan Institute for Health Security)

[P-08]Norovirus epidemiology 2017-2023: before, during and after the COVID-19 pandemic

*Julian Wei-Tze Tang^1,2, Paul W Bird^2,1, Joshua Nazareth^1,2, Judi Gardener², Abdulhakim Mreh³, Dipak Patel³, Cristina Celma⁴, Stuart Beard⁴, Oliver TR Toovey² (1. Respiratory Sciences, University of Leicester, Leicester, UK, 2. Clinical Microbiology, University Hospitals of Leicester NHS Trust, Leicester, UK, 3. Pathology Data and Informatics, University Hospitals of Leicester NHS Trust, Leicester, UK, 4. Enteric Virus Unit, National Infection Service, Health Security Agency, London, UK)

[P-09]SARS-CoV-2 mRNAワクチンの頻回接種によるIgGサブクラス動態：初期変化とその長期安定性

*Kaori Sano¹, Hideaki Kato², Akihide Ryo³, Hideki Hasegawa¹, Kei Miyakawa¹ (1. Influenza Research Center, National Institute of Infectious Diseases, Japan Institute for Health Security, 2. Infection Prevention and Control Department, Yokohama City University Hospital, 3. Department of Bioinformatics and Integrative Omics, National Institute of Infectious Diseases, Japan Institute for Health Security)

[P-10]COVID-19 mRNAワクチン接種と帯状疱疹罹患との関連：Self-controlled case series methodによる検討

*Satoko Ohfuji¹, Nozomu Toyama², Hisao Muto³, Kyoko Kondo⁴, Wakaba Fukushima¹ (1. Department of Public Health, Osaka Metropolitan University Graduate School of Medicine, 2. Toyama Dermatologic Clinic, 3. Kusuri no Aoki Co., Ltd., 4. OMU Core Facilities Life Sciences Section, Osaka Metropolitan University)

[P-11]新型コロナワクチン追加接種による感染および発症予防効果

*Xiuqiong Bi¹, Yujia Sun¹, Tomoko Takayama¹, Tetsushi Mizuno¹, Akinori Hara¹, Hiroyuki Nakamura¹, Hiroyasu Ooe¹, Masaharu Tokoro¹, Hiroshi Ichimura¹ (1. Kanazawa University)

[P-12]The Effect of Host Immune Response to Rotavirus Vaccine with the Gut Microbiome

*Yuki Higashimoto¹, Hiroyuki Hiramatsu⁶, Masaru Ihira², Yoshiki Kawamura^3,4, Hiroki Miura³, Jun-Ichi Kawada³, Masashi Hotta⁵, Jun Kunisawa⁵, Tetsushi Yoshikawa³ (1. Department of Clinical Microbiology, Fujita Health University School of Medical Sciences, 2. Department of Clinical Science for Biological Monitoring, Fujita Health University School of Medical Sciences, 3. Department of Pediatrics, Fujita Health University School of Medicine, 4. Department of Pediatrics, Fujita Health University Okazaki Medical Center, 5. Microbial Research Center for Health and Medicine, National Institutes of Biomedical Innovation, Health and Nutrition (NIBN), 6. Center for Clinical Trial and Research Support, Fujita Health University)

[P-13]健常成人を対象としたワクチン臨床試験における効率的運営体制の構築と課題への対応

*Maki Owada¹, Michiko Koga^2,3, Fumitaka Nagamura¹, Minako Kono¹, Riyo Owada^1,4, Saori Minote¹, Hiroe Kakegawa¹, Megumi Isobe¹ (1. Center for Translational Research,IMSUT Hospital, The Institute of Medical Science, The University of Tokyo, 2. Department of Infectious Diseases, The University of Tokyo Pandemic Preparedness Infection and Advanced Research Center (UTOPIA), the University of Tokyo,, 3. Department of Infectious Diseases and Applied Immunology, IMSUT Hospital, The Institute of Medical Science, the University of Tokyo, 4. Department of Inspection,IMSUT Hospital, The Institute of Medical Science, The University of Tokyo)

[P-14]妊婦に対する百日咳含有ワクチン接種の抗体応答と反応原性及び児への移行抗体に関する研究：沖縄Study（第2報）

*Tatsuya Yoshihara¹, Masashi Kamiya², Satoko Ohfuji³, Junko Manabe¹, Hiroko Kumashiro⁴, Yoshiko Miura¹, Shin Irie⁵, Toshihiro Tanaka⁶, Kenji Okada⁷, Wakaba Fukushima³ (1. SOUSEIKAI Fukuoka Mirai Hospital Clinical Research Center, 2. Kamiya Haha To Ko No Clinic, 3. Department of Public Health, Osaka Metropolitan University Graduate School of Medicine, 4. SOUSEIKAI Innovation and Strategic Business, 5. SOUSEIKAI, 6. Department of Pediatrics, Shizuoka Kosei Hospital, 7. Fukuoka Nursing College)

[P-15]A型インフルエンザウイルスに結合するDNAアプタマーの開発

*Yukitoshi Katayama¹, Naoki Nomura², Toshiki Sekiya², Tomomi Kawakita², Yuna Imaizumi¹, Eri Hamada¹, Hiroshi Kida², Hirofumi Sawa³, Masashi Shingai², Katsunori Horii¹ (1. NEC solution Innovators, Ltd., 2. Hokkaido University International Institute for Zoonosis Control, 3. Hokkaido University Institute for Vaccine Research and Development)

[P-16]発光性ウイルス様粒子を用いた高病原性鳥インフルエンザ中和抗体の迅速評価系の開発

*Makoto Ota^1,2, Kaori Sano², Fumitaka Momose³, Noriko Kishida², Tomoko Arita², Yasushi Suzuki², Masayuki Shirakura², Hideki Asanuma², Shinji Watanabe², Hideki Hasegawa^1,2, Kei Miyakawa² (1. Infection and Pathology, Medical Sciences, Graduate School of Medicine, Tohoku Univ., 2. Research Center for Influenza, Japan Institute for Health Security, 3. Department of Diagnostic Testing and Technology Research, Japan Institute for Health Security)

[P-17]5歳未満の小児重症肺炎死亡例における呼吸器病原体のメタゲノム解析

*Yusuke Sayama¹, Takeaki Imamura¹, Michiko Okamoto¹, Mayuko Saito¹, Hitoshi Oshitani² (1. Department of Virology, Tohoku University Graduate School of Medicine, 2. Department of Global Health and Infectious Diseases, Tohoku University Graduate School of Medicine)

[P-18]網羅的遺伝子診断技術を用いた感染性胃腸炎病原体解析

*Ken Sugata¹, Azusa Kawaguchi², Yoshiki Kawamura⁴, Hidetaka Nakai³, Tomoyuki Mizukami⁵, Hideki Mori⁶, Hiroki Miura⁷ (1. Mie National Hospital, 2. Hokkado medical center, 3. Tohokawa city hospital, 4. Fujita Health Univ. Okazaki medical center, 5. Kumamoto medical center, 6. Nagasaki medical center, 7. Fujita Health Univ.)

[P-19]下痢症ウイルス遺伝子検査における仮想陽生コントロール検体の作製と安定化の検討

*Sara Taniguchi¹ (1. Department of Virology TOYAMA INSTITUTE OF HEALTH)

[P-20]当院における感染性胃腸炎入院患者のMultiplex PCR法による原因微生物解析

*YUKA MIHARA^1,2, Shun Imamura¹, Natsuko Matsui³, Hitoshi Kuramae³, Saki Imai¹, YUKA Ohashi¹, Arika Murase¹, Souichirou Ishimaru¹, Masayuki Hirai¹, Hiroshi Kawaguchi¹, Satoru Kisohara¹ (1. Department of Pediatrics, Kariya Toyota General Hospital, 2. Meitetsu Hospital Vaccinations Center, 3. Department of Clinical Laboratory, Kariya Toyota General Hospital)

[P-21]東北メディカル・メガバンク計画三世代コホート（児童および若年成人）におけるcytomegalovirusおよびEpstein-Barr virus抗体保有率

*Eiichi N Kodama¹, Mami Ishikuro¹, Taku Obara¹, Masatsugu Orui¹, Kazuki Kumada¹, Hisaaki Kudo¹, Soichi Ogishima¹, Naoki Nakaya¹, Atsushi Hozawa¹, Shinichi Kuriyama¹, Katja Engelberg¹, Enejda Senko², Laura H Hendrix², Osamu Kogawara², John D Diaz-Decaro² (1. Tohoku University, 2. Moderna, Inc.)

[P-22]HPVワクチンにおけるインターネット上の情報収集と感情的反応の関連性
ーキャッチアップ接種対象者に焦点をあててー

*Sanae Inoue¹, Kei Fuji² (1. University of Tsukuba Graduate School of Comprehensive Human Sciences , 2. University of Tsukuba)

[P-23]RSウイルス母子免疫ワクチンに対する妊婦の意識調査

*Mai Okuyama¹, Noriko Kitamura², Miho Shibamura¹, Sayaka Takanashi¹, Saeko Morino¹, Motoi Suzuki² (1. Japan Institute for Health Security, National Institute of Infectious Diseases, Department of Immunization Research, 2. Japan Institute for Health Security, National Institute of Infectious Diseases, Center for Infectious Disease Epidemiology)

[P-24]日本のRSV感染予防における母体ワクチンおよびモノクローナル抗体の費用対効果

*Noriko Kitamura^1,2, Kaja Abbas², Tetsuya Kimura¹, Motoi Suzuki¹ (1. Japan Institute for Health Security, 2. Nagasaki University School of Global Health and Tropical Medicine)

[P-25]Pregnant women and their partners' awareness and acceptance of prevention of RSV infection in infants: a national cross-sectional web-based survey

*Megumi Hara¹, Yuichiro Nishida¹, Takuma Furukawa¹, Ai Sakakibara¹, Toshiko Nakamura¹, Takashi Matono², Wakaba Fukushima³ (1. Saga University, 2. Saga University Hospital, 3. Osaka Metropolitan University)

[P-26]Safety of mRNA-1273 Booster Doses in Asian Populations: A Literature Review of Post-Marketing Observational Studies

Daina Esposito¹, Veronica Urdaneta¹, Amanda Buttery², Chris Clarke², *Tomoharu Iino³, Piyali Mukerjee⁴ (1. Moderna, Inc., Cambridge, MA, USA, 2. Moderna, Asia Pacific, Melbourne Australia, 3. Moderna Japan (Non-author presenter), 4. Moderna, Asia Pacific Singapore)

[P-27]富山県における新型コロナウイルス変異株の流入状況と大都市との比較

*Kotoha Yoshida¹, Shunsuke Yazawa¹, Masae Itamochi¹, Kei Fukuyama¹, Yumiko Saga¹, Takahisa Shimada¹, Sara Taniguchi¹, Kazunori Oishi², Hideki Tani¹ (1. Department of Virology TOYAMA INSTITUTE OF HEALTH, 2. TOYAMA INSTITUTE OF HEALTH)

[P-28]ミャンマーにおける小児急性呼吸器感染症患者からのアデノウイルスの検出と遺伝子型解析

*Yuko Suzuki¹, Jun Tachikawa¹, Yuta Aizawa¹, Kazuhiro Kamata^1,2, Tatsuki Ikuse¹, Su Mon Kyaw Win², Lasham Di Ja², Khin Nyo Thein³, Aye Thida⁴, Yadanar Kyaw⁴, Htay Htay Tin⁵, Hisami Watanabe², Reiko Saito⁶, Akihiko Saitoh¹ (1. Department of Pediatrics, Niigata University Graduate School of Medical and Dental Science, 2. Infectious Disease Research Center of Niigata University in Myanmar,, 3. Yankin Children Hospital Yangon Myanmar,, 4. University of Medicine 2, Yangon, Myanmar,, 5. University of Medical Technology, Yangon, Myanmar, 6. Division of International Health, Niigata University Graduate School of Medical and Dental Sciences)

[P-29]Human mastadenovirus B3 diversity changes in Japan for a 10 years period

*Gabriel Gonzalez¹, Hirofumi Sawa¹ (1. Institute for Vaccine Research and Development, Hokkaido University)

[P-30]埼玉県における2024年秋季の手足口病の流行について

*Shoichiro Ino¹, Kyoko Tomioka¹, Tsuyoshi Kishimoto¹ (1. Saitama Prefectural Institute of Public Health)

[P-31]愛知県におけるノロウイルスの流行状況と遺伝子解析

*Yoshihiro Yasui¹, Noriko Nakamura¹, Yuki Suwa¹, Emi Hirose¹ (1. Aichi Prefectural Institute of Public Health)

[P-32]感染症流行予測調査の結果を用いた風疹第5期追加的対策実施前後の抗体保有率の推移

*Ai Hayashi^1,2, Fuka Kikuchi¹, Yoshio Mori¹, Kazuya Mitsuhashi³, Rika Komagome³, Wakana Okita⁴, Erina Kinugawa⁵, Hidenori Nagaki⁶, Yuki Wakabayashi⁶, Yuko Kawai⁷, Kyoka Hyodo⁷, Hitomi Yahata⁸, Wakaba Okada⁹, Michiya Hasegawa⁹, Group Kansensyochousa (1. Japan Institute for Health Security National Institute of Infectious Diseases, 2. Tohoku University Graduate School of Medicine , 3. Hokkaido Institute of Public Health, 4. Miyagi Prefectural Institute of Public Health and Environment, 5. Ibaraki Prefectural Institute of Public Health, 6. Tochigi Prefectural Institute of Public Health and Environmental Science, 7. Gunma Prefectural Institute of Public Health and Environmental Sciences, 8. Chiba Prefectural Institute of Public Health, 9. Tokyo Metropolitan Institute of Public Health)

[P-33]日本人におけるCOVID-19ワクチン初回接種完了と性格特性の関連性：Big Five（性格の5因子モデル）を用いた横断的調査

*Mamitsu Takamatsu^1,2,3, Mikiko Tokiya⁴, Megumi Hara⁵ (1. Japan Institute for Health Security National Institute of Infectious Diseases Department of Immunization Research, 2. Nagasaki University Institute of Tropical Medicine Department of Pediatric Infectious Diseases, 3. Health and Global Policy Institute, 4. Saga University Faculty of Medicine, Department of Social and Environmental Medicine, 5. Saga University Faculty of Medicine, Department of Preventive Medicine)

[P-34]大学新入生のMRワクチン接種状況と抗体価

*Yumiko Komori¹ (1. Faculty of Pharmacy, Meijo University)

[P-35]ロタウイルスワクチン導入を経た50年間の世界のWa-like G1/G3ロタウイルス分子進化の概要：1974-2020

*Yuya Fukuda¹, Yoshimasa Kudou¹, Shuhei Adachi¹, Toru Higuchi¹, Noritaka Shinatani¹, Atsuo Togashi¹, Takeshi Tsugawa¹ (1. Department of Pediatrics, Sapporo Medical University School of Medicine)

[P-36]学校における児童生徒等の予防接種歴確認の実施状況

*Saeko Morino¹, Motoi Suzuki¹ (1. National Institute of Infectious Diseases, Japan Institute for Health Security)

[P-37]自治体が実施する任意接種ワクチンの独自助成の実施状況

*Haruhisa Fukuda¹ (1. Kyushu Univ.)

[P-38]流行株抗原を保持する組換え弱毒ムンプスウイルスの作製

*Kaoru Yamano^1,2, Naoya Shiraishi^1,2, Kotaro Ishida^1,2, Noriko Matsugu², Takeshi Sugimoto^1,2, Yasuyuki Gomi², Hirotaka Ebina^1,2 (1. Virus Vaccine Group, BIKEN Innovative Vaccine Research Alliance Laboratories, Research Institute for Microbial Diseases, University of Osaka, 2. The Research Foundation for Microbial Diseases of Osaka University)

[P-39]重症免疫不全ラットを用いたSARS-CoV-2持続感染モデルの確立：ウイルス変異と長期排出の病態解析

*Kaya Miyazaki^1,2, Nozomi Shiwa-Sudo¹, Naoko Iwata-Yoshikawa¹, Yusuke Sakai¹, Kazuto Yoshimi³, Tomoji Mashimo³, Tadaki Suzuki¹, Hideki Hasegawa^1,2, Noriyo Nagata¹ (1. National Institute of Infectious Diseases, Japan Institute for Health Security, 2. Graduate School of Medicine, Tohoku University , 3. The University of Tokyo)

[P-40]2024年に福岡県で検出されたエコーウイルス25新規変異株の分子疫学解析

*Takashi Furutani¹, Hideaki Yoshitomi¹, Yuri Kondo¹, Takayuki Kobayashi¹, Mitsuhiro Hamasaki¹ (1. Fukuoka Institute of Health and Environmental Sciences)

[P-41]腸管感染ウイルスの分子系統解析による血清型の予測

*Kana Kidera¹, Yuya Fukuda², Miyu Kameda¹, Kei Haga¹, Reiko Todaka¹, Kazuhiko Katayama¹ (1. (1)Laboratory of Viral Infection Control, Ōmura Satoshi Memorial Institute, Graduate School of Infection Control Sciences, Kitasato University, 2. (2)Department of Pediatrics, Sapporo Medical University)

[P-42]猫伝染性腹膜炎における血清中サイトカイン／ケモカインの解析と抗ウイルス薬治療の奏効を予測するバイオマーカーの探索

*Naoya Maekawa¹, Akiko Nishida², Masahiro Tamura², Hayato Nakamura¹, Tomohiro Okagawa¹, Shiro Murata¹, Kazuhiko Ohashi¹, Satoru Konnai^1,3 (1. Laboratory of Infectious Diseases, Department of Disease Control, Faculty of Veterinary Medicine, Hokkaido University, 2. Companion Animal Internal Medicine, Department of Companion Animal Clinical Sciences, School of Veterinary Medicine, Rakuno Gakuen University, 3. Institute for Vaccine Research and Development (HU-IVReD), Hokkaido University)

[P-43]新型コロナウイルス交差中和抗体に対する抗イディオタイプ抗体の単離とワクチンへの活用

*YIMEI WANG¹, Saya Moriyama¹, Yu Adachi¹, Akira Ainai², Kenta Nakano³, Tadashi Okamura³, Tadaki Suzuki², Hiroshi Itou⁴, Yoshimasa Takahashi¹ (1. Research Center for Vaccine Development, National Institute of Infectious Diseases, Japan Institute for Health Security, 2. Department of Infectious Disease Pathology, National Institute of Infectious Diseases, Japan Institute for Health Security, 3. Department of Laboratory Animal Medicine, National Institute of Global Health and Medicine, Japan Institute for Health Security, 4. Drug Discovery Research, Chiome Bioscience Inc.)

[P-44]経鼻コロナワクチン研究のためのマウス・サル・ヒトの粘膜検体における高感度機能性抗体価測定系の構築

*Meito Shibuya^1,2,3, Takahito Ito³, Mina Yamamoto³, Hiroshi Kiyono^1,2,4,5,6,7, Fujihashi Kohtaro^1,2,7,8,9 (1. Department of Human Mucosal Vaccinology, Chiba University Hospital, Chiba, 2. Synergy Institute for Futuristic Mucosal Vaccine Research and Development (cSIMVa), Chiba University, Chiba, 3. Vaccine R&D Laboratory, Vaccine Business Division, Shionogi & Co., Ltd., 4. Future Medicine Education and Research Organization, Chiba University, Chiba, 5. Department of Medicine, UC San Diego School of Medicine, San Diego, CA, USA, 6. CU-UCSD Center for Mucosal Immunology, Allergy and Vaccines (cMAV), UC San Diego School of Medicine, San Diego, CA, USA, 7. Division of Infectious Disease Vaccine R&D, Research Institute of Disaster Medicine, Chiba University, Chiba, 8. Division of Mucosal Vaccines, International Vaccine Design Center, The Institute of Medical Science, The University of Tokyo, Tokyo, 9. Department of Pediatric Dentistry, The University of Alabama at Birmingham, Birmingham AL, USA)

[P-45]ワクチン免疫原性強化を可能にするSARS-CoV-2 spike由来ヘルパーT細胞エピトープの探索

*Kazutaka Terahara¹, Takashi Sato², Masanori Isogawa³, Saori Tachibana³, Hiroko Miyadera⁴, Tomohiro Takano¹, Ryutaro Kotaki⁵, Taishi Onodera¹, Yu Adachi¹, Saya Moriyama¹, Takayuki Matsumura¹, Masaharu Shinkai⁶, Yoshimasa Takahashi¹ (1. Research Center for Vaccine Development, National Institute of Infectious Diseases, Japan Institute for Health Security, 2. Advancing Aqua Regeneration Research at Shinshu University, 3. Department of Virology II, National Institute of Infectious Diseases, Japan Institute for Health Security, 4. Department of Medical Genetics, Institute of Medicine, University of Tsukuba, 5. Department of Molecular Systems Immunology, The University of Tokyo Pandemic Preparedness, Infection and Advanced Research Center (UTOPIA), 6. Tokyo Shinagawa Hospital)

[P-46]COVID-19ワクチン接種後に形成される抗原抗体複合体による副反応メカニズムの解析

*Mizuki Fujisawa¹, Tsuyoshi Takeishi^1,2, Saya Moriyama¹, Yu Adachi¹, Ohta Shinichiro³, Miwa Morikawa³, Masaharu Shinkai³, Takayuki Matsumura¹, Yoshimasa Takahashi¹ (1. Japan Institute for Health Security, National Institute of Infectious Diseases, Research Center for Vaccine Development, 2. Kitasato University, School of Science, Department of Biosciences, 3. Tokyo Shinagawa Hospital)

[P-47]ネクロトーシスに着目した経鼻全粒子不活化インフルエンザワクチンの免疫賦活化機構の解明

*Eita Sasaki^1,2, Hideki Asanuma¹, Yoshimasa Takahashi², Hideki Hasegawa¹ (1. National Institute of Infectious Diseases, Japan Institute for Health Security, Influenza Research Center, 2. National Institute of Infectious Diseases, Japan Institute for Health Security, Research Center for Vaccine Development)

[P-48]製造基材の違いに着目したインフルエンザワクチン様HAタンパク質の糖鎖修飾パターン解析

*Ryuichi Sugiyama¹, Haruna Nishijima¹, Kayoko Sato², Toru Takenga^1,3, Noriko Shimasaki¹, Yusuke Nakai^1,3,4, Yuichi Harada¹, Akihide Ryo⁴ (1. Japan Institute for Health Security (JIHS) National Institute of Infectious Diseases (NIID) Influenza Research Center, 2. Japan Institute for Health Security (JIHS) National Institute of Infectious Diseases (NIID) Department of Respiratory Viruses, 3. Japan Institute for Health Security (JIHS) National Institute of Infectious Diseases (NIID) Department of Diagnostic Testing and Technology Research, 4. Japan Institute for Health Security (JIHS) National Institute of Infectious Diseases (NIID) Department of Bioinformatics and Integrative Omics)

[P-49]国家備蓄ワクチン（A/Astrakhan/3212/2020, IDCDC-RG71A）のフェレットを用いた有効性評価

*Hideki Asanuma Asanuma¹, Yasuji Suzuki¹, Tomoko Arita¹, Eita Sasaki¹, Masayuki Shirakura¹, Noriko Kishida¹, Kaori Sano¹, Noriyo Nagata¹, Naoko Yoshikawa Iwata¹, Yusuke Sakai¹, Nozomi Shiwa¹, Tadaki Suzuki¹, Hidekaki Inui², Tetsuro Tanabe², Hideki Hasegawa¹ (1. Japan Institute for Health Security, 2. KM Biologics Co., Ltd.)

[P-50]糖鎖修飾の異なるインフルエンザワクチンにより誘導される抗体の性状解析

*Kayoko Sato¹, Mina Nakauchi², Kazuya Nakamura², Hideki Hasegawa², Hitoshi Takahashi² (1. Japan Institue for Health Security, National Institute of Infectious Diseases, Department of Respiratory Viruses, 2. Japan Institue for Health Security, National Institute of Infectious Diseases, Influenza Research Center)

[P-51]Evaluation of the potency of a hemagglutinin–adjuvant integrated nanovaccine against Influenza virus infection

*Ryuji Takeichi¹, Koki Murata¹, Naohiro Hayakawa¹, Masahiro Wakao¹, Hiroyuki Shinchi¹ (1. Grad. Sch.Sci.and Eng., Kagoshima Univ.)

[P-52]Evaluating the Potential of Inactivated Whole Virus Particle Influenza Vaccines to Induce Functionally Effective Immune Response

*Toshiki Sekiya^1,2,3,4, Tomomi Kawakita², Mamiko Kawahara¹, Marumi Ohno^1,3,5, Naoki Nomura^1,2, Masashi Shingai^1,2,3, Hiroshi Kida^1,2,3 (1. Division of Biologics Development, International Institute for Zoonosis Control, Hokkaido University, 2. Institute for Vaccine Research and Development (HU-IVReD), Hokkaido University, Sapporo, Japan, 3. International Collaboration Unit, International Institute for Zoonosis Control, Hokkaido University, Sapporo, Japan, 4. The Department of Microbiology and Immunology, The University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, Australia, 5. One Health Research Center, Hokkaido University, Sapporo, Japan)

[P-53]A型インフルエンザウイルス増殖におけるIGF2BP1の機能解析と、ウイルス高増殖細胞の作製への応用

*Mina Nakauchi¹, Kazuya Nakamura¹, Hideki Hasegawa¹, Hitoshi Takahashi¹ (1. Influenza Research Center, National Institute of Infectious Diseases, Japan Institute for Health Security)

[P-54]北海道で哺乳動物から分離されたA(H5N1)鳥インフルエンザウイルスを活用したA(H5N1)ワクチン候補株と自然分離株の抗原性について

*Shinji Saito¹, Satoshi Osaki¹, Koshiro Tabata¹, Atsuko Inoue¹, Yukari Itakura¹, Gabriel Gonzalez¹, Takahiro Hiono², Norikazu Isoda³, Shinji Watanabe⁴, Hideki Asanuma⁴, Hideki Hasegawa⁴, Yoshihiro Sakoda³, Hirofumi Sawa¹ (1. Institute for Vaccine Research and Development: HU-IVReD, Hokkaido University, 2. One Health Research Center, Hokkaido University, 3. Faculty of Veterinary Medicine, Hokkaido University, 4. Japan Institute for Health Security, National Institute of Infectious Diseases, Research Center for Influenza)

[P-55]狂犬病経口ワクチンプラットフォーム確立に向けた基盤構築

*Yukari Itakura¹, Koshiro Tabata¹, Shinji Saito¹, Gabriel Gonzalez¹, Hirofumi Sawa^1,2,3 (1. Institute for Vaccine Research and Development, Hokkaido University, 2. International Institute for Zoonosis Control, Hokkaido University, 3. One Health Research Center, Hokkaido University)

[P-56]スクアレンベースアジュバントA-910823の有効性と副反応の誘導メカニズム

*Anri Yoshioka¹, Yuya Yoshioka¹, Kouji Kobiyama², Tomoya Hayashi², Yujiro Kidani¹, Yosuke Yanagida³, Junpei Kasahara³, Yoshiji Asaoka⁴, Akimasa Yoshimura¹, Satoru Ishida¹, Shinya Omoto¹, Morio Nagira¹, Cevayir Coban⁵, Ken J Ishii² (1. Vaccine R&D Laboratory, Shionogi & Co., Ltd., 2. Division of Vaccine Science, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo (IMSUT), 3. Vaccine Manufacturing Technology Research Laboratory, Shionogi & Co., Ltd., 4. Laboratory for Drug Discovery and Development, Shionogi & Co., Ltd., 5. Division of Malaria Immunology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo (IMSUT))

[P-57]Synergistic activation of innate immunity by a dual-TLR-ligand nanoadjuvant

*Takato Yamasaki¹, Koki Murata¹, Ryo Jufuku¹, Issa Fukuda¹, Masahiro Wakao¹, Hiroyuki Shinchi¹ (1. Grad. Sch. Sci. and Eng., Kagoshima Univ.)

[P-58]自己集合性ペプチドゲルCK2はアジュバント／抗原のキャリアとして抗インフルエンザ免疫を誘導できる

*Koubun Yasuda¹, Miya Fujimoto², Etsushi Kuroda¹ (1. Department of Immunology, Hyogo Medical University School of Medicine, 2. Menicon Co. Ltd.)

[P-59]Effects of chronic social defeat stress on vaccine- and adjuvant-induced immune responses.

*Etsushi Kuroda¹, Masakiyo Nakahira¹, Takumi Adachi¹, Kazufumi Matsushita ¹, Koubun Yasuda¹ (1. Hyogo Medical University School of Medicine)

[P-60]連続波1270 nm近赤外光が有するワクチンアジュバント効果の波長特異性の検討

*Yohei Maki¹, Tomoya Sano¹, Eri Yasue¹, Shusaku Takahashi¹, Takunori Ogawa¹, Toshihiro Kushibiki², Takeshi Ono³, Etsuko Kitagami¹, Nagisa Tokunoh⁴, Yasuo Yoshioka⁴, Kei Mikita³, Miya Ishihara², Yoshifumi Kimizuka¹ (1. Division of Infectious Diseases and Respiratory Medicine, National Defense Medical College, 2. Department of Medical Engineering, National Defense Medical College, 3. Department of Global Infectious Diseases and Tropical Medicine, National Defense Medical College, 4. Research Institute for Microbial Diseases, Osaka University)

[P-61]連続波近赤外光を用いた物理的アジュバントによる粘膜投与型ワクチンへの応用可能性

*Tomoya Sano¹, Yohei Maki¹, Eri Yasue¹, Shusaku Takahashi¹, Takunori Ogawa¹, Toshihiro Kushibiki², Takeshi Ono³, Etsuko Kitagami¹, Kei Mikita³, Miya Ishihara², Yoshifumi Kimizuka¹ (1. Division of Infectious Diseases and Respiratory Medicine, Department of Internal Medicine, National Defense Medical College, 2. Department of Medical Engineering, National Defense Medical College, 3. Department of Global Infectious Diseases and Tropical Medicine, National Defense Medical College)

[P-62]ワクチン副反応メカニズムの解明を目指した免疫プロファイリング解析

*Tomohiro Takano¹, Hitoshi Iuchi², Michiaki Hamada², Masaharu Shinkai³, Takayuki Matsumura¹, Yoshimasa Takahashi¹ (1. Research Center for Vaccine Development, National Institute of Infectious Diseases, Japan Institute for Health Security, 2. Faculty of Science and Engineering, Waseda University, 3. Tokyo Shinagawa Hospital)

[P-63]マウス感染モデルを用いた Mycobacterium abscessus に対する感染防御免疫の解析

*Mineo Watanabe¹, Noriko Shinoda¹, Takuto Nagamine¹, Fuka Ogi¹, Nozomi Sakurai¹, Mirei Arai¹, Masaki Uchida¹, Satoshi Mitarai² (1. NIhon Pharmaceutical University, 2. Research Institute of Tuberculosis, Japan Anti-Tuberculosis Association)

[P-64]Pre-S1領域に対する抗体を顕著に誘導可能な生体肝移植者向け皮内投与型Ｂ型肝炎ワクチンに適したアジュバントの検討

*Natsumi Koike¹, Shintaro Onishi¹, Takatoshi Niitsu², Wataru Hariu², Atsuko Otsuka¹, Yuki Ito³, Chinatsu Ohashi³, Yasunori Oda³, Yasumasa Goh³, Masaki Yamamoto¹, Takehiko Tohjo², Takuya Mori¹ (1. Biological-Material Science Research, Kao Corporation, 2. Processing Development Research, Kao Corporation, 3. Beacle Incorporated)

[P-65]ヒトアデノウイルス経口ワクチンの現状と課題に関する検討・・・第2報

*Nozomu Hanaoka¹, Kenichiro Takahashi¹, Kousuke Murakami¹ (1. Laboratory of Unidentified Pathogen Investigation Department of Diagnostic Testing and Technnology Research National Institute of Infectious Diseases Japan Institute for Health Security)

[P-66]ヒト肺サーファクタント由来の抗原運搬型人工合成粘膜アジュバントSF-10を用いた経口インフルエンザワクチンの腸管粘膜長期免疫記憶の解析

*Satoko Sakai¹, Takashi Kimoto^2,1, Etsuhisa Takahashi¹, Takako Sawabuchi¹, Keiko Kameda¹, Hiroshi Kido¹ (1. Tokushima Univ., 2. Kobe Gakuin Univ.)

[P-67]質量分析を用いた新型インフルエンザワクチンHA含量測定系の構築

*Yusuke Nakai^1,2,3, Ryuichi Sugiyama², Yuichi Harada², Noriko Shimasaki², Haruna Nishijima², Toru Takenaga^1,2, Akihide Ryo³ (1. Japan Institute for Health Security (JIHS) National Institute of Infectious Diseases (NIID) Department of Diagnostic Testing and Technology Research, 2. Japan Institute for Health Security (JIHS) National Institute of Infectious Diseases (NIID) Influenza Research Center, 3. Japan Institute for Health Security (JIHS) National Institute of Infectious Diseases (NIID) Department of Bioinformatics and Integrative Omics)

[P-68]インフルエンザHAワクチンの力価試験用一次標準抗原に及ぼす不活化処理法の評価

*Toru Takenaga^1,2, Tomoko Kuwahara³, Noriko Shimasaki², Haruna Nishijima², Kayoko Sato⁴, Keiko Murano², Yusuke Nakai^1,2, Ryuichi Sugiyama², Hiyori Okura², Shigeyuki Itamura^2,5, Yuichi Harada², Hideki Hasegawa² (1. Japan Institute for Health Security (JIHS) National Institute of Infectious Diseases (NIID) Department of Diagnostic Testing and Technology Research, 2. Japan Institute for Health Security (JIHS) National Institute of Infectious Diseases (NIID) Influenza Research Center, 3. Japan Institute for Health Security (JIHS) National Institute of Infectious Diseases (NIID) Center for Public Health Action in Applied Epidemiology , 4. Japan Institute for Health Security (JIHS) National Institute of Infectious Diseases (NIID) Department of Respiratory Viruses, 5. Japan Institute for Health Security (JIHS) National Institute of Infectious Diseases (NIID) Department of International Cooperation)

[P-69]季節性インフルエンザワクチン及び新型コロナウイルスワクチンの製造株の変更に係る迅速な薬事手続に関する取組みについて

*Takashi Ogawa¹, Tsuyoshi Ando¹, Eiko Iwasa¹, Chika Uchiyama¹, Rinka Kaneyama¹, Kengo Kawachi¹, Kenji Sawanobori¹, Soni Ju¹, Hiroyuki Hiramatsu¹, Junichi Fukuchi¹, Shun Masuta¹, Jurika Murakami¹, Yoko Yabuki¹, Satoshi Yoshida¹, Yuji Matsukura¹ (1. Pharmaceuticals and Medical Devices Agency)

[P-70]枯草菌由来膜小胞を担体とするPlug-and-Display型ワクチンの開発

*Kimihiro Abe¹, Takehito Wakabayashi², Ryoma Nakao¹, Takehiro Yamaguchi¹, Tsutomu Sato^2,3, Yukihiro Akeda¹ (1. Dept. Bac I, NIID, JIHS, 2. Fac. Sci. Eng., Hosei Univ., 3. Dept. Front. Biosci., Hosei Univ.)

[P-71]Improvement of Viral Vaccine Upstream Production with Peptone Supplementations

*Kentaro Kuroki¹ (1. Thermo Fisher Scientific)

[P-72]ウイルス産生向上のためのPVAマイクロキャリア〈スキャポバ®〉を用いた高密度培養の検討

*Yota Imahori¹, Natsuki Murata², Toru Itagaki¹, Akio Fujita¹, Tomoyoshi Komiya² (1. Kuraray Co., Ltd., 2. Hokuriku University Faculty of Health Sciences)

[P-73]百日咳菌由来の外膜小胞を用いた経鼻百日咳ワクチンの検討と課題

Sora Ishikawa^1,2, Kei Asayama^1,2, Rena Sakamoto^1,2, Koji Tamura², Ryoma Nakao³, Tadaki Suzuki¹, *Akira Ainai^1,2 (1. Department of Infectious Disease Pathology, National Institute of Infectious Diseases, Japan Institute of Health Security, 2. Department of Biological Science and Technology, Faculty of Advanced Engineering, Tokyo University of Science, 3. Department of Bacteriology I National Institute of Infectious Diseases, Japan Institute of Health Security)

[P-74]RSV感染患者の鼻咽頭ぬぐい液におけるウイルス排出と抗RSV F蛋白抗体の関連性評価

*Shiori Ueno¹, Akira Ainai¹, Sho Miyamoto¹, Takeshi Arashiro^1,2, Kunihiro Oba^3,4, Kenichiro Takahashi⁵, Tadaki Suzuki¹ (1. Department of Infectious Disease Pathology, National Institute of Infectious Diseases, Japan Institute for Health Security, 2. Sanofi Vaccines Medical, Tokyo, Japan, 3. Department of Pediatrics, Showa General Hospital, 4. Department of Infection Control and Prevention, Showa General Hospital, 5. Department of Diagnostic Testing and Technology Research, National Institute of Infectious Diseases, Japan Institute for Health Security)

[P-75]当院におけるCOVID-19院内感染に対するAirdogⓇの効果の検討

*SATOSHI MARUMO^1,2, Mayu Nagata¹, Kanako Umeji¹, Hiromi Hama¹ (1. Department of Infection Control, Medical Research Institute KITANO HOSPITAL, 2. Department of Respiratory Medicine, Medical Research Institute KITANO HOSPITAL)

[P-76]新型コロナ感染後急性後遺症もしくはコロナワクチン接種後に発症した筋痛性脳脊髄炎・慢性疲労症候群の症例に対するビタミンD補充療養指導のランダム化比較試験

*Shinichiro Kodama¹, Masato Yoshino², Akinori Fujisawa³, Mutsuo Naganuma⁴, Yuki Kobayashi⁵, Satoshi Teramukai⁶, Mitsuko Nakata⁶, Masanori Fukushima⁷ (1. Medical company Soreiyukai, 2. Yoshino clinic, 3. Honbetsu Cardiovascular Medicine Clinic, 4. Tokachimutumino Clinic, 5. Kobayashi Clinic, 6. Kyoto Prefectural University, 7. Learning Health Society Institute)

[P-77]Apical-Out Airway Organoidを用いたヒトコロナウイルスHKU-1感染評価系の構築

*Masatoshi Kakizaki¹, Satoko Sugimoto^1,2, Miyuki Kawase¹, Koichi Hashimoto³, Kazuya Shirato¹ (1. Department of Respiratory viruses, National Institute of Infectious Diseases, Japan Institute for Health Security., 2. Research Center for Biosafety, Laboratory Animal and Pathogen Bank, National Institute of Infectious Diseases, Japan Institute for Health Security., 3. Department of Pediatrics, School of Medicine, Fukushima Medical University.)